Terms: = Prostate cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Staging
1601 results:
1. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
2. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
3. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
4. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
5. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract] [Full Text] [Related]
6. Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
Albo G; Gallioli A; Ripa F; De Lorenzis E; Boeri L; Bebi C; Rocchini L; Longo F; Zanetti SP; Turetti M; Piccoli M; Montanari E
BMC Urol; 2024 Mar; 24(1):64. PubMed ID: 38515053
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer.
Deka H; Pooleri GK; Suguna B; Rajeshkannan R; Sekhar R; Bindhu MR; Prasad V
World J Urol; 2024 Mar; 42(1):153. PubMed ID: 38483621
[TBL] [Abstract] [Full Text] [Related]
8. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
9. Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
Bennett R; Li EV; Ho AY; Aguiar JA; Neill C; Rowe SP; Patel HD; Savas H; Ross AE
Prostate; 2024 Jun; 84(8):717-722. PubMed ID: 38450787
[TBL] [Abstract] [Full Text] [Related]
10. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
11. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
12. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract] [Full Text] [Related]
13. Biparametric MRI for Local staging of prostate cancer: Current Status and Future Applications.
Dell'atti L
Anticancer Res; 2024 Feb; 44(2):463-470. PubMed ID: 38307562
[TBL] [Abstract] [Full Text] [Related]
14. Intraductal prostate cancer Affinity for Lymphatic-Predominant Metastases Through
Bernardino R; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Tiwari R; Cockburn J; Leão R; Metser U; Berlin A; van der Kwast T; Fleshner NE
J Urol; 2024 Apr; 211(4):586-593. PubMed ID: 38299501
[TBL] [Abstract] [Full Text] [Related]
15. The Ability of the STAR-CAP staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
16. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to prostate cancer Imaging : Complementary Role in PSMA-Negative Cases.
Ergül N; Çermik TF; Alçın G; Arslan E; Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Baykal Koca S; Türkay R; Yücetaş U
Clin Nucl Med; 2024 Mar; 49(3):e105-e110. PubMed ID: 38271254
[TBL] [Abstract] [Full Text] [Related]
17. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
18. Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer.
Ali I; Rezk M; Hamouda D; Talaat O; Omar Y; Abdel Tawab M; Nasr I
Br J Radiol; 2024 Feb; 97(1155):622-631. PubMed ID: 38265254
[TBL] [Abstract] [Full Text] [Related]
19. Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
Aggarwal P; Krishna Kumar RG; Das CJ; Kubihal V; Subudhi TK; Khan MA; Kumar R
Br J Radiol; 2024 Jan; 97(1153):195-200. PubMed ID: 38263835
[TBL] [Abstract] [Full Text] [Related]
20. Incidental carcinoma of the prostate in cystoprostatectomy specimens - is it always a toothless lion?
Dema V; Croitor A; Floruncuţ A; Dema S; Bardan TR; Tăban SM; Barna RA; Natarâş BR; Cumpănaş AA
Rom J Morphol Embryol; 2023; 64(4):501-507. PubMed ID: 38184830
[TBL] [Abstract] [Full Text] [Related]
[Next]
